ClinicalTrials.gg
CompletedNCT03464864Updated Oct 30, 2018

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

A Phase 1 interventional study of Treprostinil Inhalation Powder in Pulmonary Arterial Hypertension, sponsored by Mannkind Corporation. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2018-10-30.

Sponsored by Mannkind Corporation · Phase 1, Interventional, and Other

From the registry’s dates

  • Primary completion was Jun 2018, 8 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 1
Study type
Interventional
Enrollment
36
Allocation
Non-randomized
Ages
18 Years to 55 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 44 studies testing treprostinil in Pulmonary Arterial Hypertension — 3 open to participants now, 5 under way, 2 of them phase 3. treprostinil · Pulmonary Arterial Hypertension.

Enrollment
18th of 44
36 · median 32
Started
2018
with 2 others
Phase 1
9 of 44
none open now
Registered
33rd of 44
by date
Lead sponsor
1 of 44
Mannkind Corporation

Among the 44 studies testing treprostinil in Pulmonary Arterial Hypertension, this one is the 18th largest by enrollment, is one of 3 that started in 2018, is one of 9 in phase 1, and was the 33rd registered.

Pulmonary Arterial Hypertension

699 studies on the registry are indexed under Pulmonary Arterial Hypertension; 140 are open to participants now.

Browse Pulmonary Arterial Hypertension studies →

Open to participants now

3 of the 44 studies testing treprostinil in Pulmonary Arterial Hypertension are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

About treprostinil

treprostinil: first FDA approval 2002 (REMODULIN), first EMA approval 2020. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 90 Pulmonary Arterial Hypertension studies recruiting now, 51 (57%) set no upper age limit and 24 (27%) stop at 75 or younger; 18 take children under 18; 11 take healthy volunteers.

This study: 18 Years to 55 Years · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 44 studies testing treprostinil in Pulmonary Arterial Hypertension, or all of them as a file.
02

Study summary

A Dose-Rising Clinical Trial to Evaluate the Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

Read the detailed description

Up to 48 subjects will be enrolled in 8 cohorts of 6 subjects each. The treatments are intended to establish the maximum tolerated dose in healthy normal volunteers, starting at 30 mcg. Each subject will receive one dose of Treprostinil Inhalation Powder by oral inhalation during the treatment period.

A total of 12 pharmacokinetic blood samples will be collected from each subject. Plasma pharmacokinetic samples will be analyzed for treprostinil.

03

Conditions studied

  • Pulmonary Arterial Hypertension
04

Who can participate

Ages eligible
18 Years to 55 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Voluntarily consents to participate in this study and provides written prior to the start of any study-specific procedures.
  2. Male or female. Females must not be pregnant or breastfeeding.
  3. Is between 18 and 55 years of age (inclusive).
  4. Female subjects must weigh between 55 and 100 kg, inclusive, with a (BMI) between 19.0-32.0 kg/m2, inclusive. Male subjects must weigh between 55 and 120 kg, inclusive, with a BMI between 19.0-32.0 kg/m2, inclusive.
  5. Females must be of non- (defined as surgically sterile [i.e. had a bilateral tubal ligation, hysterectomy, or bilateral oophorectomy at least 6 months prior to the first dose of study medication] or for at least 1 year prior to the first dose of study medication) or agree to use an acceptable form of (see Section 4.4) from screening until 14 days after study completion.
  6. Medical history, physical examination, oropharyngeal examination, vital signs, , spirometry, and clinical laboratory results within normal limits or considered not by the Investigator at screening.

Exclusion criteria

Exclusion Criteria:

  1. History or presence of cardiovascular, pulmonary, hepatic, renal, hematologic, gastrointestinal, endocrine, immunologic, dermatologic, neurologic, oncologic, or psychiatric disease or any other condition that, in the opinion of the Investigator, would jeopardize the safety of the subject or the validity of the study results.
  2. A clinically significant abnormal finding on the physical exam, medical history, (ECG), or clinical laboratory results at screening.
  3. History of chronic lung disease such as asthma, (COPD), cystic fibrosis, interstitial lung disease, pulmonary fibrosis, etc.
  4. History of migraine headaches.
  5. History of a bleeding abnormalities (i.e., gingival bleeding, epistaxis, or blood on toilet paper, etc.) that is judged to be significant by the Investigator.
  6. Has (FEV1)/ forced vital capacity (FVC) ratio \< 80% predicted or FEV25-75 \<50% predicted.
  7. History of anaphylaxis, a documented reaction, or a clinically significant idiosyncratic reaction to any drug.
  8. Has been on a significantly abnormal diet (as determined by the Investigator) during the 4 weeks preceding the first dose of study medication.
  9. Has participated in another clinical trial (and received an product) within 30 days prior to the first dose of study medication.
  10. Use of any over-the-counter (OTC) medication (including nutritional or dietary supplements, herbal preparations, or vitamins) within 7 days prior to the first dose of study medication until the end of study visit without evaluation and approval by the Medical Monitor.
  11. Use of any prescription medication, except hormonal or hormonal replacement therapy, from 14 days prior to the first dose of study medication until the end-of-study visit without evaluation and approval by the Investigator.
  12. Has been treated with any known drugs that are moderate or strong inhibitors/inducers of cytochrome P450 (CYP) enzymes (e.g., barbiturates, phenothiazines, cimetidine, carbamazepine) within 30 days prior to the first dose of study medication, and that, in the Investigator's judgment, may impact subject safety or the validity of the study results.
  13. Blood or plasma donation within 30 days prior to the first dose of study medication.
  14. Smoking or use of tobacco- or nicotine-containing products within 6 months prior to the first dose of study medication until the end-of-study visit.
  15. Engagement in strenuous exercise within 48 hours prior to the first dose of study medication.
  16. Consumption of beverages or foods that contain alcohol, grapefruit, poppy seeds, broccoli, Brussels sprouts, pomegranate, star fruit, char-grilled meat, or caffeine/xanthine from 48 hours prior to the first dose of study medication until the end-of-study visit. Subjects will be instructed not to consume any of the above products; however, allowance for an isolated single incidental consumption may be evaluated and approved by the study Investigator based on the potential for interaction with the study drug.
  17. Has any prior history of substance abuse or treatment (including alcohol).
  18. Is a female with a positive pregnancy test result or who is breastfeeding.
  19. Has a positive urine screen for drugs of abuse (amphetamines, barbiturates, benzodiazepines, cocaine, cannabinoids, opiates) or cotinine.
  20. Has a positive test for surface antigen, antibody, or (HIV) at screening or has been previously treated for hepatitis B, hepatitis C, or HIV infection.
  21. Unwilling to remove any artificial nails (e.g. acrylic, gel) or fingernail polish and to not use such products for the duration of the study.
  22. Inability to perform study procedures including pulmonary function testing.
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

ECG (electrocardiogram)

A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Phase 1
Primary purpose
Other
Allocation
Non-randomized
Intervention model
Single group
Masking
None (open label)
Enrollment
36 participants (actual)

Study arms

  • Experimental
    Treprostinil Inhalation Powder 30 mcg

    Drug: Treprostinil Inhalation Powder

  • Experimental
    Treprostinil Inhalation Powder 60 mcg

    Drug: Treprostinil Inhalation Powder

  • Experimental
    Treprostinil Inhalation Powder 90 mcg

    Drug: Treprostinil Inhalation Powder

  • Experimental
    Treprostinil Inhalation Powder 120 mcg

    Drug: Treprostinil Inhalation Powder

  • Experimental
    Treprostinil Inhalation Powder 150 mcg

    Drug: Treprostinil Inhalation Powder

  • Experimental
    Treprostinil Inhalation Powder 180 mcg

    Drug: Treprostinil Inhalation Powder

  • Experimental
    Treprostinil Inhalation Powder 240 mcg

    Drug: Treprostinil Inhalation Powder

  • Experimental
    Treprostinil Inhalation Powder 300 mcg

    Drug: Treprostinil Inhalation Powder

Interventions

06

What researchers measure

Primary outcomes

  1. Incidence and severity of treatment-related adverse events (safety and tolerability) of single ascending doses of Treprostinil Inhalation Powder

    Incidence and severity of treatment-related adverse events determined by changes from screening (baseline) of findings from physical examinations, laboratory evaluations, vital signs measurements, pulmonary testing, and ECG measurements.

    Time frame: At protocol-specified time points from the time of screening (day 0) to end of study (day 6)

Secondary outcomes

  1. Systemic exposure and pharmacokinetics of treprostinil administered as Treprostinil Inhalation Powder in healthy normal volunteers

    Concentration of treprostinil in blood as measured by protocol-specified pharmacokinetic parameters (eg maximum concentration, time to maximum concentration).

    Time frame: At protocol-specified time points throughout day 1

  2. Dose proportionality

    Dose proportionality of increasing doses of Treprostinil Inhalation Powder in healthy normal volunteers as measured by maximum blood concentration of treprostinil.

    Time frame: 10 months

07

Study locations

1 site
  • Investigational Site 441
    San Antonio, Texas 78217, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Jun 2018, 2 months.

Of 34 industry-sponsored phase 1 interventional studies under Pulmonary Arterial Hypertension, half reached primary completion within 5 months of starting (the median), counting those still running; a quarter within 2 and three quarters within 17. This study's 2 months is below that.

Counting every sponsor, half of 45 studies reached it within 9 months; a quarter within 2 and three quarters within 22.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 1, 2018
First posted
Mar 14, 2018
StartActual
Mar 9, 2018
Primary completionActual
Jun 5, 2018
CompletionActual
Jun 5, 2018
Last update
Oct 30, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Oct 30, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03464864
Responsible party
Sponsor
First posted
Mar 14, 2018
Start date
Mar 9, 2018
Primary completion
Jun 5, 2018
Completion
Jun 5, 2018
Last update
Oct 30, 2018

Study contacts

Senior Director, Clinical Pharmacology
study director · Mannkind Corporation

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Oct 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Treprostinil

Start the discussion